AdipoRon’s Impact on Alzheimer’s Disease—A Systematic Review and Meta-Analysis
Open accessThe DOI matches its Crossref record; 159 of the 159 references it cites were found in a registry or an index.
Abstract
Alzheimer’s disease (AD) remains a leading cause of cognitive decline and mortality worldwide, characterized by neurodegeneration, synaptic deficiencies, and neuroinflammation. Despite advancements in early detection, diagnosis, and treatment, AD presents substantial challenges due to its complex pathology, heterogeneity, and the limited efficacy of current therapies. Consequently, there is a pressing need for novel therapeutic agents to target the multifaceted aspects of AD pathology, enhance current treatments, and minimize adverse effects. AdipoRon, an adiponectin receptor agonist, has garnered interest for its potential neuroprotective effects, including reducing neuroinflammation, improving mitochondrial function, and mitigating tau hyperphosphorylation. This review aimed to evaluate the effects of AdipoRon-based adiponectin replacement therapy against AD, using a comprehensive approach grounded in the PICO framework—Population, Intervention, Comparison, and Outcomes. A total of six studies were reviewed, including in vitro and in vivo investigations examining AdipoRon’s impact on various AD models. These studies involved different cell lines and transgenic mouse models, assessing various outcomes such as cognitive function, neuroinflammation, tau phosphorylation, synaptic deficiencies, and relevant molecular pathways. By synthesizing data from these studies, our review thoroughly explains AdipoRon’s neuroprotective effects, mechanisms of action, and potential as a therapeutic agent for AD. This analysis aims to highlight the current state of knowledge, identify gaps in the research, and suggest directions for future studies and clinical applications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Molecular Structure of AdipoRon. AdipoRon, with the molecular formula C27H28N2O3, has a molecular weight of 428.5 g/mol. Its exact mass is 428.20999276 Da, aligning with its monoisotopic mass. The compound exhibits high lipophilicity, with an XLogP3-AA value of 4.7, indicating it is more soluble in fats than water. It has one hydrogen bond donor and four hydrogen bond acceptors, suggesting its capacity for hydrogen bonding and potential interactions with other molecules. AdipoRon features eight rotatable bonds, reflecting its structural flexibility. Its topological polar surface area is 58.6 Å2, suggesting moderate polarity, influencing its ability to cross biological membranes. With a heavy atom count of 32, AdipoRon is relatively complex, and its complexity value of 582 further supports this. The compound is electrically neutral with a formal charge of 0 and lacks chiral centers, indicating no stereoisomerism. These properties highlight AdipoRon’s lipophilic nature, structural complexity, and potential behavior in biological contexts [91].](https://figures.cochat.ai/paper-figures/85896b4f34ab4a24b9787b4a09323f06/adiporons-impact-on-alzheimers-diseasea-systematic-review-and-meta-analysis-figure-1.jpg)

![Figure 3 Meta-analysis for overall effects of AdipoRon on novel object preference [99,102].](https://figures.cochat.ai/paper-figures/967fc847edb04f83ba7e8a43a096c0d1/adiporons-impact-on-alzheimers-diseasea-systematic-review-and-meta-analysis-figure-3.jpg)
![Figure 4 Meta-analysis for overall effects of AdipoRon on time spent in the novel arm [100,102].](https://figures.cochat.ai/paper-figures/08a4dd2995a74a4bbea17ac1bacf756b/adiporons-impact-on-alzheimers-diseasea-systematic-review-and-meta-analysis-figure-4.jpg)
![Figure 5 Meta-analysis for overall effects of AdipoRon on time spent in the target quadrant [100,101,102].](https://figures.cochat.ai/paper-figures/1678195445784af1a3d66f21e5dc3f32/adiporons-impact-on-alzheimers-diseasea-systematic-review-and-meta-analysis-figure-5.jpg)
![Figure 6 Meta-analysis for overall effects of AdipoRon on total arm entries [98,100].](https://figures.cochat.ai/paper-figures/50d052ad2bcf43da976526708ba8bd40/adiporons-impact-on-alzheimers-diseasea-systematic-review-and-meta-analysis-figure-6.jpg)
![Figure 7 Meta-analysis for overall effects of AdipoRon on escape latency [98,99,100,101].](https://figures.cochat.ai/paper-figures/2dabb579da9c4ce482e35d4e0adc99a2/adiporons-impact-on-alzheimers-diseasea-systematic-review-and-meta-analysis-figure-7.jpg)
![Figure 8 Meta-analysis for overall effects of AdipoRon on swimming speed [99,100].](https://figures.cochat.ai/paper-figures/c0bcb40479694244be77e35054e97fbd/adiporons-impact-on-alzheimers-diseasea-systematic-review-and-meta-analysis-figure-8.jpg)
![Figure 9 Meta-analysis for overall effects of AdipoRon on crossing times [98,99].](https://figures.cochat.ai/paper-figures/05fc3ef1d46140b097d9fcbae21c557e/adiporons-impact-on-alzheimers-diseasea-systematic-review-and-meta-analysis-figure-9.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Elevated postsynaptic activity triggers BDNF release and TrkB receptor activation, which in turn engages mechanistic target of rapamycin complex 1 (mTORC1) dependent translational programs supporting dendritic spine growth and synaptic strengthening [20,42,48,49,50].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [50]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The PRISMA 2020 statement: An updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · BMJ · doi:10.1136/bmj.n71 · Cited by 108,283
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139 · cited 1×
“We interpreted 0–40% as unimportant, 30–60% as moderate heterogeneity, 50–75% as substantial heterogeneity, and 75–100% as considerable heterogeneity [94,95].”
Quantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763 · cited 1×
“We interpreted 0–40% as unimportant, 30–60% as moderate heterogeneity, 50–75% as substantial heterogeneity, and 75–100% as considerable heterogeneity [94,95].”
Analysing data and undertaking meta‐analyses
Deeks, J. J., Higgins, J. P., Altman, D. G., & on behalf of the Cochrane Statistical Methods Group (2019) · Cochrane Handbook for Systematic Reviews of Interventions · doi:10.1002/9781119536604.ch10 · Cited by 2,672 · cited 1×
“We imposed a random-effect model, as this more conservative method permitted the study heterogeneity to deviate beyond chance, providing further generalizable results [96].”
AMPK: Mechanisms of Cellular Energy Sensing and Restoration of Metabolic Balance
Garcia, D., & Shaw, R. J. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.05.032 · Cited by 1,978 · cited 2×
“…stress responses [83,84]. studies have shown that AdipoRon can activate similar signaling pathways to adiponectin, such as the Adenosine Monophosphate ‐ Activated Protein Kinase (AMPK) pathway [74,77,79–82], which plays a role in regulating energy metabolism and cellular stress responses [83,84].”
The Amyloid-β Pathway in Alzheimer’s Disease
Hampel, H., Hardy, J., Blennow, K., Chen, C., Perry, G., Kim, S. H., Villemagne, V. L., Aisen, P., Vendruscolo, M., Iwatsubo, T., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01249-0 · Cited by 1,952
The blood–brain barrier: Structure, regulation and drug delivery
Wu, D., Chen, Q., Chen, X., Han, F., Chen, Z., & Wang, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01481-w · Cited by 1,906 · cited 1×
“Furthermore, AdipoRon’s ability to regulate autophagy is significant, as autophagic dysfunction is implicated in the accumulation of toxic protein aggregates and cellular debris, exacerbating neurodegenerative processes.”
Adiponectin as an anti-inflammatory factor
Ouchi, N., & Walsh, K. (2007) · Clinica Chimica Acta · doi:10.1016/j.cca.2007.01.026 · Cited by 872
A small-molecule AdipoR agonist for type 2 diabetes and short life in obesity
Okada-Iwabu, M., Yamauchi, T., Iwabu, M., Honma, T., Hamagami, K.-I., Matsuda, K., Yamaguchi, M., Tanabe, H., Kimura-Someya, T., Shirouzu, M., et al. (2013) · Nature · doi:10.1038/nature12656 · Cited by 757
Alzheimer's Disease: Treatment Strategies and Their Limitations.
Passeri, E., Elkhoury, K., Morsink, M., Broersen, K., Linder, M., Tamayol, A., Malaplate, C., Yen, F. T., & Arab-Tehrany, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213954 · Cited by 689 · cited 1×
“This complex and progressive disease disrupts daily functioning and quality of life for millions worldwide, underscoring the urgent need for innovative and effective treatment strategies [29–31].”
Research works printed but not linked: 2
- Ramakrishnan N. Auger K. Rahimi N. Jialal I. Biochemistry, Adiponectin StatPearls StatPearls Publishing LLC. Treasure Island, FL, USA 2024 30725726
- National Library of Medicine, National Library of Medicine-National Institute of Health. AdipoRon Available online: https://pubchem.ncbi.nlm.nih.gov/compound/AdipoRon (accessed on 22 July 2024)
Cited by
de Lima, E. P., Laurindo, L. F., Catharin, V. C. S., Direito, R., Tanaka, M., Jasmin Santos German, I., Lamas, C. B., Guiguer, E. L., Araújo, A. C., Fiorini, A. M. R., et al. (2025) · Metabolites · doi:10.3390/metabo15020124 · Cited by 94
Self-citationParkinson’s Disease: Bridging Gaps, Building Biomarkers, and Reimagining Clinical Translation
Tanaka, M. (2025) · Cells · doi:10.3390/cells14151161 · Cited by 56
Self-citationParkinson’s Disease: Bridging Gaps, Building Biomarkers, and Reimagining Clinical Translation
Tanaka, M. (2025) · doi:10.20944/preprints202506.2099.v2 · Cited by 57
Self-citationNeuroinflammation and Natural Antidepressants: Balancing Fire with Flora
Figueiredo Godoy, A. C., Frota, F. F., Araújo, L. P., Valenti, V. E., Pereira, E. D. S. B. M., Detregiachi, C. R. P., Galhardi, C. M., Caracio, F. C., Haber, R. S. A., Fornari Laurindo, L., et al. (2025) · Biomedicines · doi:10.3390/biomedicines13051129 · Cited by 32
Self-citationQuinoline Quest: Kynurenic Acid Strategies for Next-Generation Therapeutics via Rational Drug Design
Tanaka, M., Szatmári, I., & Vécsei, L. (2025) · Pharmaceuticals · doi:10.3390/ph18050607 · Cited by 29
Self-citationKounatidis, D. C., Vallianou, N. G., Karampela, Ι., Grivakou, E., & Dalamaga, Μ. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.05.013 · Cited by 41
Quinoline Quest: Kynurenic Acid Strategies for Next-Generation Therapeutics via Rational Drug Design
Tanaka, M., Szatmári, I., & Vécsei, L. (2025) · doi:10.20944/preprints202503.2399.v1 · Cited by 30
Self-citationTanaka, M., Battaglia, S., & Liloia, D. (2025) · Biomedicines · doi:10.3390/biomedicines13051045 · Cited by 24
“These findings energize ongoing efforts to combat and possibly reverse cognitive decline [93,94].”
Self-citationFrom Microbial Switches to Metabolic Sensors: Rewiring the Gut–Brain Kynurenine Circuit
Tanaka, M., & Vécsei, L. (2025) · Biomedicines · doi:10.3390/biomedicines13082020 · Cited by 23
“Evidence from metabolic interventions, including AdipoRon treatment, supports the notion that correcting mitochondrial and inflammatory dysfunctions can mitigate neurodegenerative processes [125].”
Self-citationFrom Microbial Switches to Metabolic Sensors: Rewiring the Gut–Brain Kynurenine Circuit
Tanaka, M., & Vécsei, L. (2025) · doi:10.20944/preprints202506.0880.v1 · Cited by 24
Self-citationTanaka, M., Araujo, A. C., Valenti, V. E., Guiguer, E. L., Catharin, V. C. S., Gualhardi, C. M., de Souza Bastos Mazuqueli Pereira, E., de Alvares Goulart, R., de Argolo Haber, R. S., de Carvalho, A. C. A., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27052370 · Cited by 13
Self-citationMartos, D., Lőrinczi, B., Szatmári, I., Vécsei, L., & Tanaka, M. (2025) · Cells · doi:10.3390/cells14130973 · Cited by 12
“Concurrently, KYNA modulates neuroimmune interactions, suppressing pro-inflammatory cytokine release (e.g., TNF-α , IL-6) and microglial activation, thereby attenuating chronic neuroinflammation linked to disorders such as multiple sclerosis and depression [27,39–43].”
Self-citationMartos, D., Lőrinczi, B., Szatmári, I., Vécsei, L., & Tanaka, M. (2025) · doi:10.20944/preprints202504.1511.v2 · Cited by 13
Self-citationNeurogenesis and Neuroinflammation in Dialogue: Mapping Gaps, Modulating Microglia, Rewiring Aging
Tanaka, M. (2026) · Cells · doi:10.3390/cells15010078 · Cited by 11
“These compounds demonstrate robust CNS exposure and have been shown to lower neuroinflammatory biomarkers in humans, offering a promising route to intervene in age-related cognitive decline and mild cognitive impairment [221,284].”
Self-citationChehadi, A. C., Pereira de Lima, E., Detregiachi, C. R. P., Santos de Argollo Haber, R., Catharin, V. M. C. S., Fornari Laurindo, L., Engracia Valenti, V., Machado Galhardi, C., Tanaka, M., & Maria Barbalho, S. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27010465 · Cited by 8
“…higher cytokine loads predict smaller hippocampi, poorer memory, and deeper anhedonia, while agents that either quiet neuroimmune signaling or re-energize neurogenesis—such as Akebia saponin D, liraglutide, naringenin, or KYN-pathway modulators—restore plasticity and relieve symptoms [105,108–111].”
Self-citationSpecial Issue “Translating Molecular Psychiatry: From Biomarkers to Personalized Therapies”
Tanaka, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262010238 · Cited by 8
“Pilot human studies of AdipoRon will test whether its multi-target effects observed in preclinical models can translate into meaningful outcomes in AD [34,91,92].”
InfluentialSelf-citationSzabó, Á., Galla, Z., Spekker, E., Martos, D., Szűcs, M., Fejes-Szabó, A., Fehér, Á., Takeda, K., Ozaki, K., Inoue, H., et al. (2025) · Cells · doi:10.3390/cells14211711 · Cited by 7
Self-citationAdipoRon as a Novel Therapeutic Agent for Depression: A Comprehensive Review of Preclinical Evidence
Laurindo, L. F., Rodrigues, V. D., Mellem, R. H., Haber, R. S. D. A., Valenti, V. E., Laurindo, L. F., Chagas, E. F. B., de Oliveira, C. M., Direito, R., Miglino, M. A., et al. (2025) · Biomedicines · doi:10.3390/biomedicines13081867 · Cited by 6
“…a systematic review and meta-analysis assessed the effects of AdipoRon administration in preclinical models of Alzheimer’s disease, demonstrating AdipoRon’s beneficial impacts on modulating neuroinflammation and reducing dementia symptoms and pathways in various preclinical experiments [24].”
Self-citationAlzenaidi, F., Aldoweesh, O. H., Alghofaili, S., Fadel, A., Lasloom, R. A. A., Alharbi, D., Almalki, F. S., Alkhairi, A. A., Alharbi, M., Alhamdan, N. A., et al. (2025) · Metabolism Open · doi:10.1016/j.metop.2025.100389 · Cited by 3
“This gap is concerning given the increasing recognition of metabolic dysfunction as both a risk factor for and consequence of AD progression [23,24].”
Gheibi, F., Hosseini, L., Kalejahi, P., Dastgiri, S., Shafiee‐Kandjani, A. R., & Noorazar, S. G. (2026) · Molecular Brain · doi:10.1186/s13041-026-01323-0 · Cited by 1
Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery
Tanaka, M. (2026) · Biomedicines · doi:10.3390/biomedicines14061265
Self-citationLi, J., Jiang, L., 晁凤蕾, Zhang, L., 胡春年, Zhou, Y., Wang, S., Pan, Q., Luo, Y., Tang, J., et al. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03907-7
Metadata
- Authors
- Barbalho, S. M., Laurindo, L. F., de Oliveira Zanuso, B., da Silva, R. M. S., Gallerani Caglioni, L., Nunes Junqueira de Moraes, V. B. F., Fornari Laurindo, L., Dogani Rodrigues, V., da Silva Camarinha Oliveira, J., Beluce, M. E., Penteado Detregiachi, C. R., Barbalho Lamas, C., dos Santos Haber, J. F., Cavallari Strozze Catharin, V. M., Quesada, K., Tanaka, M., & Valenti, V. E.
- Affiliations
- São Paulo State Technological College (BR)
- Faculdade de Medicina de São José do Rio Preto (BR)
- Department of Biochemistry and Pharmacology, School of Medicine, Universidade de Marília (UNIMAR), Marília 17525-902, São Paulo, Brazil
- Department of Biochemistry and Pharmacology, School of Medicine, Faculdade de Medicina de Marília (FAMEMA), Marília 17519-030, São Paulo, Brazil
- Department of Biochemistry and Pharmacology, School of Medicine, Faculdade de Medicina de São José do Rio Preto (FAMERP), São José do Rio Preto 15090-000, São Paulo, Brazil
- Universidade de Marília (BR)
- Department of Gerontology, School of Gerontology, Universidade Federal de São Carlos (UFSCar), São Carlos 13565-905, São Paulo, Brazil
- University of Szeged (HU)
- Autonomic Nervous System Center, School of Philosophy and Sciences, São Paulo State University, Marília 17525-902, São Paulo, Brazil
- Corresponding author
- Tanaka, Masaru
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2025-01-08
- Volume
- 26
- Issue
- 2
- Pages
- 484
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC11765103
- OpenAlex
- W4406170873
- Cited by
- 18
- References
- 148
- Citations by year
- 2026: 6 · 2025: 12
- FWCI
- 2.36
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- Preprints.org (acceptedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- HUN-REN Hungarian Research Network
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- AdipoRon, adiponectin receptor agonist, Alzheimer's disease, neuroprotection, neuroinflammation, tau hyperphosphorylation, synaptic dysfunction, mitochondrial function, cognitive function, transgenic mouse model, neurodegeneration
- MeSH terms
- Alzheimer Disease, Animals, Disease Models, Animal, Humans, Indenes, Piperidines, tau Proteins, Neuroprotective Agents, Adiponectin, Receptors, Adiponectin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.